Friday, July 15, 2016, 37 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $87.69 to $104,800,000.00.

Highlighted Stocks Traded by Insiders:

HealthEquity (HQY) - FREE Research Report

Sacks Ian, who is Director at HealthEquity, sold 100,000 shares at $30.27 on July 15, 2016. Following this transaction, the Director owned 173,417 shares meaning that the stake was reduced by 36.57% with the 100,000-share transaction.

The shares most recently traded at $29.89, down $0.38, or 1.27% since the insider transaction. Historical insider transactions for HealthEquity go as follows:

  • 4-Week # shares sold: 35,000
  • 12-Week # shares sold: 35,000
  • 24-Week # shares bought: 75,500
  • 24-Week # shares sold: 35,000

The average volume for HealthEquity has been 327,000 shares per day over the past 30 days. HealthEquity has a market cap of $1.8 billion and is part of the technology sector and computer software & services industry. Shares are up 19.62% year-to-date as of the close of trading on Friday.

HealthEquity, Inc. provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company has a P/E ratio of 91.5. Currently, there are 7 analysts who rate HealthEquity a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on HQY - FREE

TheStreet Quant Ratings rates HealthEquity as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and premium valuation. Get the full HealthEquity Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Federal Agricultural Mortgage (AGM) - FREE Research Report

Junkins Lowell, who is Director at Federal Agricultural Mortgage, sold 2,000 shares at $38.75 on July 15, 2016. Following this transaction, the Director owned 10,347 shares meaning that the stake was reduced by 16.2% with the 2,000-share transaction.

Everson Dennis A, who is Director at Federal Agricultural Mortgage, sold 1,500 shares at $38.38 on July 15, 2016. Following this transaction, the Director owned 1,780 shares meaning that the stake was reduced by 45.73% with the 1,500-share transaction.

Faivre-Davis Sara Louise, who is Director at Federal Agricultural Mortgage, sold 1,900 shares at $38.10 on July 15, 2016. Following this transaction, the Director owned 6,922 shares meaning that the stake was reduced by 21.54% with the 1,900-share transaction.

The shares most recently traded at $38.03, down $0.07, or 0.18% since the insider transaction. Historical insider transactions for Federal Agricultural Mortgage go as follows:

  • 4-Week # shares bought: 100
  • 4-Week # shares sold: 300
  • 12-Week # shares bought: 100
  • 12-Week # shares sold: 3,115
  • 24-Week # shares bought: 100
  • 24-Week # shares sold: 3,115

The average volume for Federal Agricultural Mortgage has been 66,400 shares per day over the past 30 days. Federal Agricultural Mortgage has a market cap of $395.3 million and is part of the financial sector and financial services industry. Shares are up 20.49% year-to-date as of the close of trading on Friday.

Federal Agricultural Mortgage Corporation provides a secondary market for various loans made to borrowers primarily in the United States. It operates through four segments: Farm & Ranch, USDA Guarantees, Rural Utilities, and Institutional Credit. The stock currently has a dividend yield of 2.75%. The company has a P/E ratio of 8.5. Currently, there is 1 analyst who rates Federal Agricultural Mortgage a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AGM - FREE

TheStreet Quant Ratings rates Federal Agricultural Mortgage as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. Get the full Federal Agricultural Mortgage Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ciena (CIEN) - FREE Research Report

Smith Gary B, who is President, Ceo at Ciena, sold 8,000 shares at $19.65 on July 15, 2016. Following this transaction, the President, Ceo owned 767,884 shares meaning that the stake was reduced by 1.03% with the 8,000-share transaction.

The shares most recently traded at $20.05, up $0.40, or 1.99% since the insider transaction. Historical insider transactions for Ciena go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 39,938
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 108,100
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 140,900

The average volume for Ciena has been 3.3 million shares per day over the past 30 days. Ciena has a market cap of $2.7 billion and is part of the technology sector and telecommunications industry. Shares are down 3.33% year-to-date as of the close of trading on Friday.

Ciena Corporation provides equipment, software, and services that support the transport, switching, aggregation, service delivery, and management of voice, video, and data traffic on communications networks worldwide. The company has a P/E ratio of 194.8. Currently, there are 13 analysts who rate Ciena a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CIEN - FREE

TheStreet Quant Ratings rates Ciena as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, unimpressive growth in net income and generally higher debt management risk. Get the full Ciena Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.